Introduction
============

Thymic epithelial tumors (TETs), well known for their variability in morphological appearance and for the heterogeneity of their neoplastic epithelial cells, are epithelial neoplasms originating from the thymus ([@b1-ol-0-0-7676],[@b2-ol-0-0-7676]). TETs account for 50% of the anterior mediastinal masses occurring in the adult population and represent the most common tumors of the anterior portion of the mediastinum ([@b3-ol-0-0-7676]). However, the overall incidence of TETs is rare, at 3.2 cases/1,000,000 individuals per year ([@b4-ol-0-0-7676]). The majority of patients are between the ages of 40 and 60 years at the time of diagnosis, with no significant difference between males and females with respect to the incidence of this disease ([@b5-ol-0-0-7676]). Furthermore, previous studies have demonstrated that TETs are associated with a variety of autoimmune disorders, including myasthenia gravis, pure red cell aplasia and hypogammaglobulinemia ([@b3-ol-0-0-7676],[@b5-ol-0-0-7676]).

According to the widely-accepted World Health Organization (WHO) classification system, which is based upon the morphological features and atypia of epithelial cells as well as the lymphocyte-to-epithelial cell ratio, TETs are subdivided into thymomas (types A, AB, B1, B2 and B3) and thymic carcinomas (TCs) ([@b6-ol-0-0-7676]). Thymomas are generally considered to have an indolent growth pattern with malignant transformation potential. Certain thymomas demonstrate local invasion, pleural dissemination and systemic metastasis during advanced stages, despite being indolent and non-invasive during their early stages ([@b1-ol-0-0-7676]). Furthermore, previous studies have documented the recurrence and metastasis of thymomas following resection ([@b7-ol-0-0-7676]--[@b9-ol-0-0-7676]), suggesting that even unaggressive, non-invasive thymomas possess the fundamental features of a malignant tumor. Therefore, thymomas require consideration as a potentially malignant disease requiring prolonged follow-up, despite the fact that the majority are low grade and indolent ([@b10-ol-0-0-7676]). TCs, as the most aggressive subtype of TETs, usually exhibit a more invasive phenotype with a worse survival rate, as well as a greater potential for relapse and metastasis compared with the majority of thymomas ([@b11-ol-0-0-7676]). Surgical resection remains the optimal treatment for early-stage TETs, while advanced-stage, unresectable or recurrent thymic malignancies are usually treated with palliative chemotherapy ([@b12-ol-0-0-7676]).

However, due to the rarity and morphological complexity of TETs, the biological mechanisms that facilitate TET tumorigenesis and development remain unclear at present. Additionally, biomarkers that are associated with clinical behavior and prognosis are urgently required.

Tumor invasion and metastasis are complex processes involving interactions between cancer cells and the extracellular matrix (ECM), including alterations in cell adhesion and motility that permit tumor cells to invade and migrate through the ECM ([@b13-ol-0-0-7676]). A number of these alterations develop at the contact points between cells and the ECM, which are known as focal adhesions. Focal adhesion kinase (FAK), originally identified in v-Src-transformed chicken embryo fibroblasts ([@b14-ol-0-0-7676]), is a highly conserved 125-kDa cytoplasmic, non-receptor protein tyrosine kinase that is activated and localized at the sites of cellular focal adhesions ([@b15-ol-0-0-7676]). As a critical mediator of signaling events between cells and the ECM, FAK serves a pivotal function in growth factor receptor- and integrin-mediated signal transduction pathways ([@b16-ol-0-0-7676]). The activation of FAK by integrin clustering, cell adhesion or growth factor receptors induces the rapid phosphorylation of FAK at Tyr-397, which has been identified as the major autophosphorylation site. Once phosphorylated, Tyr-397 generates a high-affinity binding site for SH2-domain-containing proteins, including Src-family kinases, phospholipase Cg and growth factor receptor-bound protein 7 ([@b17-ol-0-0-7676]). The subsequent binding of FAK to Src likely contributes to Src kinase activation, which in turn promotes the phosphorylation of FAK at additional tyrosine residues to stimulate maximal FAK kinase activity ([@b18-ol-0-0-7676]).

FAK has been implicated in the regulation of a diverse set of cellular functions, including survival, migration, proliferation, angiogenesis and apoptosis, in a variety of cell types ([@b16-ol-0-0-7676]), suggesting that FAK may contribute to tumor formation and malignant progression ([@b19-ol-0-0-7676]). Previously, FAK has also been demonstrated to serve an important role in the regulation of cancer stem cells, the epithelial-to-mesenchymal transition and the tumor microenvironment ([@b16-ol-0-0-7676],[@b20-ol-0-0-7676]). In addition, accumulating evidence has demonstrated that FAK is overexpressed in a wide range of human tumors, including colon, breast, oral, liver, head and neck tumors, gastric carcinomas and neuroblastomas ([@b21-ol-0-0-7676]--[@b28-ol-0-0-7676]). Furthermore, the overexpression of FAK has been reported to serve as an independent prognostic factor for various types of malignancies, including ovarian, esophageal and hepatocellular cancer, as well as acute myeloid leukemia ([@b29-ol-0-0-7676]--[@b32-ol-0-0-7676]).

However, despite the gradually-increasing research into various malignancies, there is insufficient data available regarding FAK expression in TETs. Therefore, the present study aimed to examine FAK expression in TETs and to determine whether FAK expression is associated with the clinical behavior and prognosis of TETs.

Materials and methods
=====================

### Patients and specimens

TET tissue specimens were obtained from 100 patients who had undergone tumor resection without preoperative chemotherapy or radiotherapy at the Department of Thoracic Surgery, Affiliated Hospital of Qingdao University (Qingdao, China) between January 2002 and December 2006. Of the 100 patients who were included in the study, 55 were male and 45 were female (male-to-female ratio of 1.22:1) and the mean age of the patients was 52.1±13.7 years (range, 19--80 years). Additionally, 28 patients (28.0%) suffered from myasthenia gravis. Tumor diameters ranged between 1.5 and 11.0 cm, with a mean diameter of 5.8±2.2 cm. TETs were classified into 84 thymomas (9 type A, 24 type AB, 15 type B1, 18 type B2 and 18 type B3) and 16 TCs, according to the 2015 WHO criteria ([@b6-ol-0-0-7676]). Furthermore, clinical stages were based upon the newly revised Masaoka-Koga staging system ([@b10-ol-0-0-7676]), with 37 stage I, 27 stage II, 23 stage III and 13 stage IV cases in the study cohort. In addition, 58 normal thymus tissues were obtained from different patients with mediastinal cysts who had undergone mediastinal cystectomy at the same institution between January 2002 and December 2006. The normal thymus tissues were used as the control group. The healthy thymus cohort consisted of 28 men and 30 women, aged 18--72 years (mean, 48.6±13.2 years). The medical records and histopathological archives of all patients were complete. Diagnoses were confirmed histologically in all specimens, based upon the examination of sections stained with hematoxylin and eosin at the Department of Pathology of the Affiliated Hospital of Qingdao University. Following surgical resection, all specimens were fixed in 10% buffered formalin overnight at room temperature prior to being embedded in paraffin. Postoperative follow-up data were obtained from all patients, with a mean follow-up period of 101.3±31.1 months (range, 3--120 months). One patient with type AB thymoma did not complete the follow-up. The present study was performed in accordance with the Declaration of Helsinki, and was approved by the Medical Ethics Committees of the Affiliated Hospital of Qingdao University. Written informed consent was obtained from all participants included in the study.

### Immunohistochemistry

Formalin-fixed, paraffin-embedded tissue sections were cut into 4-µm thick sections. Following routine deparaffinization and rehydration in descending ethanol series (100, 95, 85 and 70%) for 5 min, respectively, the sections were autoclaved in citrate buffer (pH 6.0; 0.1 M; 1 l; Zhongshan Goldenbridge Biotechnology Co., Ltd., Beijing, China) for 5 min at 120°C for antigen retrieval. Sections were then washed in PBS three times. Endogenous peroxidase activity was blocked in methanol containing 0.3% H~2~O~2~ for 30 min at room temperature. The sections were subsequently washed in PBS (3 times, for 3 min each time), prior to being incubated with a mouse anti-FAK monoclonal primary antibody 4.47 (dilution 1:200; cat. no. 05--537; EMD Millipore, Billerica, MA, USA) overnight at 4°C. Following 3 cycles of washing with PBS (for 3 min each time), the sections were incubated with the Polink-1 horseradish peroxidase mouse for DAB Bulk kit (cat. no. D12-110; Golden Bridge International, Inc., Bothell, WA, USA), at room temperature for 15 min. All procedures were performed according to the manufacturer\'s instructions. Sections were washed again with PBS (3 times for 3 min each time), prior to being treated at room temperature with a diaminobenzidine working solution for 10 min and then counterstained with hematoxylin at room temperature for 5 min. The negative controls underwent the same procedures; however, the primary antibody was omitted or replaced with normal serum.

### Evaluation of immunohistochemistry

The presence of staining was evaluated by two board-certified pathologists who were blinded to the clinical data of the patients. FAK expression was determined using a scoring system that measured staining intensity (0, negative; 1, weak; 2, moderate; and 3, intense) and the proportion of positively-stained cells among the tumor epithelial cells (0, none; 1, 1--25%; 2, 26--50%; 3, 51--75%; and 4, 76--100%) in ≥5 areas under a light microscope (Olympus BX41; Olympus Corporation, Tokyo, Japan) at ×400 magnification. The overall staining score was obtained by multiplying the staining intensity score by the score representing the proportion of positive-stained cells. Specimens were separated into high expression (overall score ≥6) and low expression (overall score \<6) groups to more accurately determine FAK expression.

### Statistical analysis

The χ^2^ test and the Kruskal-Wallis test were used to assess the association between FAK expression and different clinicopathological parameters. Overall survival rates were calculated using the Kaplan-Meier method, and the differences between the survival curves were evaluated using the log-rank test. A Cox proportional hazards multivariate regression model was developed to identify independent significant prognostic factors. P\<0.05 was considered to indicate a statistically significant difference. SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was used to perform all analyses.

Results
=======

### FAK is expressed in TETs but not in the normal thymus

All normal thymus tissues were negative for FAK expression ([Fig. 1A](#f1-ol-0-0-7676){ref-type="fig"}). Positive immunostaining of FAK was detected at varying levels in all the TET specimens. FAK staining was localized to the cytoplasm and the membrane of the epithelial cells of the thymic tumors ([Figs. 1B-D](#f1-ol-0-0-7676){ref-type="fig"} and [2A-D](#f2-ol-0-0-7676){ref-type="fig"}). Notably, the tumor lymphocytes did not express FAK. Significantly higher FAK expression was observed in 52.0% of TETs (52/100) compared with in the normal thymus, as determined using the χ^2^ test (P\<0.001). Furthermore, FAK was weakly expressed in the majority of the less aggressive TET subtypes (types A, AB and B1 thymomas), but was upregulated in the majority of highly aggressive tumor subtypes (types B2 and B3 thymomas, and TCs).

### Associations between FAK overexpression and clinicopathological parameters in TETs

The associations between the clinicopathological characteristics of patients with TETs and FAK overexpression are summarized in [Table I](#tI-ol-0-0-7676){ref-type="table"}. A statistically significant association was observed between FAK overexpression and the Masaoka-Koga stage and WHO classification (both P\<0.001). Notably, 33/36 (91.7%) high-stage (stages III and IV) tumors overexpressed FAK, compared with only 19/64 (29.7%) low-stage (stages I and II) tumors (P\<0.001). In the less aggressive TET subtypes, the majority of tumors exhibited low FAK expression, with only 10/48 tumors (20.8%) exhibiting high FAK expression. By contrast, in the highly aggressive subtypes of TETs, 42/52 tumors (80.8%) exhibited high FAK expression. This difference between the two groups was statistically significant (P\<0.001). However, FAK expression was not associated with age, sex, tumor size or myasthenia gravis ([Table I](#tI-ol-0-0-7676){ref-type="table"}).

### Univariate and multivariate analyses of prognostic factors for patients with TETs

The 10-year overall survival rates of patients were analyzed in order to assess the prognostic significance of FAK expression, as well as that of other clinicopathological parameters ([Table II](#tII-ol-0-0-7676){ref-type="table"}). The 10-year survival rate of the high FAK expression group was significantly lower than that for the low FAK expression group in patients with TETs, as determined using the log rank test (42.3 vs. 93.7%; P\<0.001; [Fig. 3](#f3-ol-0-0-7676){ref-type="fig"}). Multivariate analysis, using the Cox proportional hazards model, of the WHO classification, Masaoka-Koga stage, tumor size and FAK expression revealed that only high FAK expression and the Masaoka-Koga stage were significant independent prognostic factors of TETs (P=0.034 and P=0.005, respectively; [Table III](#tIII-ol-0-0-7676){ref-type="table"}).

Discussion
==========

FAK, an important mediator between cells and the extracellular matrix, is considered to serve an important function in a number of biological processes, including cell adhesion, spreading, motility, proliferation, survival, apoptosis and migration ([@b33-ol-0-0-7676]). Given that the dysregulation of these processes is often associated with the development and progression of tumors, it is understandable that FAK is highly involved in human malignancies. Increased expression and elevated activity of FAK have been demonstrated by previous studies to be associated with clinicopathological features in a wide range of human cancer types ([@b21-ol-0-0-7676]--[@b23-ol-0-0-7676],[@b27-ol-0-0-7676],[@b30-ol-0-0-7676],[@b32-ol-0-0-7676],[@b34-ol-0-0-7676]), thereby suggesting a role for FAK in carcinogenesis. However, to the best of our knowledge, there has been no previous study on FAK expression in TETs, which are rare and histologically complex tumors. Therefore, the present study analyzed FAK expression and assessed its clinical value as a prognostic marker in TETs.

The results of the present study provided definitive evidence that FAK is not expressed in the normal thymus but is significantly upregulated in TETs, as determined by immunohistochemical analysis, indicating that FAK overexpression is associated with the tumorigenesis of TETs. The present study also evaluated the association between FAK expression and clinicopathological parameters in TETs. Notably, the results of the present study demonstrated that FAK overexpression was not only strongly associated with advanced stages of TETs, but was also associated with highly aggressive subtypes. Therefore, it was hypothesized that FAK may serve important functions in the invasion and metastasis of TETs. However, no statistical association was observed between FAK expression and tumor size, sex, age or myasthenia gravis in the present study.

The observation that elevated levels of FAK are detected in TETs is consistent with reports from previous studies of FAK overexpression in other types of solid tumor. For example, Cance *et al* ([@b21-ol-0-0-7676]) analyzed the expression of FAK in normal, pre-invasive and invasive human breast and colon tissues from individual patients using immunohistochemistry. In this study, FAK was weakly expressed in the majority of benign breast and colon epithelia but was overexpressed in the majority of invasive breast carcinomas and colon cancer tissues, suggesting that FAK overexpression may occur in the early stages of tumorigenesis ([@b21-ol-0-0-7676]). Additionally, Lark *et al* ([@b23-ol-0-0-7676]) observed elevated levels of FAK expression in primary colorectal carcinomas and liver metastases compared with matched healthy colorectal tissues, using quantitative polymerase chain reaction (qPCR) and immunohistochemical analyses. The results of the aforementioned study suggested that the increased expression of FAK may suppress apoptosis and promote the survival and metastasis of cancer cells ([@b23-ol-0-0-7676]). Furthermore, Itoh *et al* ([@b22-ol-0-0-7676]) used western blotting and immunohistochemical analyses to demonstrate that FAK expression was upregulated in hepatocellular carcinoma (HCC), and that it was significantly associated with portal venous invasion, indicating that FAK overexpression serves an important function in HCC progression and invasion ([@b22-ol-0-0-7676]). Another study used immunohistochemistry and reverse transcription qPCR to demonstrate that FAK was overexpressed in non-small cell lung cancer (NSCLC) and that its overexpression was associated with nodal metastasis and advanced stages of NSCLC, suggesting that FAK serves an important role in lung cancer progression and metastasis ([@b35-ol-0-0-7676]).

Notably, the present study also used univariate and multivariate analyses to demonstrate that the overexpression of FAK in patients with TETs is significantly associated with a worse overall survival rate. Therefore, these results indicated that FAK overexpression may be an independent prognostic biomarker for TETs. The results of the present study are consistent with those of previous studies that have demonstrated FAK protein overexpression to be an independent unfavorable prognostic factor in various types of tumor ([@b22-ol-0-0-7676],[@b29-ol-0-0-7676]--[@b32-ol-0-0-7676]). By contrast, it has also been reported that FAK expression was not associated with prognosis in certain types of tumor ([@b25-ol-0-0-7676],[@b26-ol-0-0-7676],[@b34-ol-0-0-7676]). Taken together, the results of these studies suggest that FAK may serve distinct roles in different types of malignancies and during different stages of tumor progression.

In the present study, the marked upregulation of FAK in TETs, particularly in the advanced stages and highly aggressive tumor subtypes, combined with the negative expression of FAK in normal thymus tissues, suggests that FAK may be a potential therapeutic target for TETs. Recently, a FAK-targeting therapeutic approach has focused primarily on blocking its kinase enzymatic activity and targeting its scaffolding function using pharmacological agents; a number of FAK-directed small molecule inhibitors, including PF-00562271, VS-4718, GSK2256098, BI853520 and PF-04554878, are undergoing clinical trials in patients with cancer ([@b16-ol-0-0-7676]). Furthermore, a combination therapy approach using FAK inhibitors against FAK signaling pathways (e.g., the phosphatidylinositol-3-kinase, protein kinase B, epidermal growth factor receptor, human epidermal growth factor receptor-2, Src, mitogen-activated protein kinase and cellular-mesenchymal-to-epithelial transition factor signaling pathways) was employed to sensitize cancer cells to chemotherapy and to increase the efficacy of drugs ([@b16-ol-0-0-7676],[@b33-ol-0-0-7676]). Considering this, the therapeutic utility of FAK inhibitors in the advanced stages of TETs remains promising. However, future clinical trials are required in order to evaluate the clinical efficacy of these approaches in the treatment of TETs.

In the present study, immunohistochemistry was performed using a monoclonal FAK-specific 4.47 antibody, which was revealed to be highly specific to human FAK in formalin-fixed, paraffin-embedded tissue sections ([@b21-ol-0-0-7676]). This antibody is able to recognize the FAK-specific epitope at the amino terminus of a molecule in order to avoid consensus sequences within the kinase domain and cross-reactivity with the FAK-related non-kinase, an autonomously expressed carboxyl-terminal fragment. Furthermore, patients who had received adjuvant preoperative chemotherapy or radiotherapy were excluded from the present study in order to eliminate the potential effects of these treatments on the immunohistochemistry results. However, the sample sizes were relatively small in the present study due to the low incidence of TETs. Therefore, further studies comprising larger cohorts in multiple treatment centers are required in order to confirm these results.

In conclusion, to the best of our knowledge, the present study is the first to provide definitive evidence that FAK expression is upregulated in TETs. FAK overexpression may serve an important role in the tumorigenesis and progression of TETs. Furthermore, the results of the present study indicated that FAK overexpression may be used as a prognostic biomarker for TET. Additionally, FAK may be a promising therapeutic target for TETs, but the precise role of FAK in TETs remains to be confirmed by further *in vivo* and *in vitro* studies.

![Representative photomicrographs of FAK immunostaining in normal thymus and less aggressive subtypes of thymic epithelial tumor. (A) Normal thymus tissues were negative for FAK expression (magnification, ×100). Weak expression of FAK was observed in (B) type A, (C) type AB and (D) type B1 thymomas (magnification, ×200). FAK, focal adhesion kinase.](ol-15-03-3001-g00){#f1-ol-0-0-7676}

![Representative photomicrographs of FAK immunostaining in highly aggressive subtypes of thymic epithelial tumor. FAK was overexpressed in (A) type B2 and (B) type B3 thymomas, and in (C) thymic carcinoma (magnification, ×200). (D) A high-power view of FAK overexpression in thymic carcinoma epithelial cells, demonstrating the intense membrane and cytoplasmic immunoreactivity for FAK (magnification, ×400). FAK, focal adhesion kinase.](ol-15-03-3001-g01){#f2-ol-0-0-7676}

![The 10-year overall survival curves of patients with thymic epithelial tumors. High expression of FAK was significantly associated with a worse prognosis (P\<0.001, log-rank test). FAK, focal adhesion kinase.](ol-15-03-3001-g02){#f3-ol-0-0-7676}

###### 

Association between FAK expression and clinicopathological parameters in 100 patients with thymic epithelial tumors.

                        FAK expression         
  ---------------- ---- ---------------- ----- ------------------------------------------------------
  Age, years                                   0.986
    ≤60            73   38               35    
    \>60           27   14               13    
  Sex                                          0.520
    Male           55   27               28    
    Female         45   25               20    
  Tumor size                                   0.097
    ≤6 cm          56   25               31    
    \>6 cm         44   27               17    
  MG                                           0.844
    Present        28   15               13    
    Absent         72   37               35    
  Classification                               \<0.001
    A, AB, B1      48   10               38    
    B2, B3, TC     52   42               10    
  Stage                                        \<0.001^[a](#tfn1-ol-0-0-7676){ref-type="table-fn"}^
    I              37     7              30    
    II             27   12               15    
    III            23   20                 3   
    IV             13   13                 0   

Kruskal-Wallis H test. FAK, focal adhesion kinase; MG, myasthenia gravis; TC, thymic carcinoma.

###### 

Univariate analyses of prognostic factors in patients with thymic epithelial tumors.

  Parameter        Total, n   10-year OS, %   P-value
  ---------------- ---------- --------------- ---------
  Age, years                                  0.100
    ≤60            73         71.2            
    \>60           27         54.9            
  Sex                                         0.645
    Male           55         65.5            
    Female         45         68.6            
  Tumor size                                  0.023
    ≤6 cm          56         76.7            
    \>6 cm         44         54.5            
  FAK expression                              \<0.001
    Low            48         93.7            
    High           52         42.3            
  MG                                          0.278
    Absent         72         63.7            
    Present        28         75.0            
  Classification                              \<0.001
    A, AB, B1      48         91.5            
    B2, B3, TC     52         44.2            
  Stage                                       \<0.001
    I and II       64         89.0            
    III and IV     36         27.8            

OS, overall survival; FAK, focal adhesion kinase; MG, myasthenia gravis; TC, thymic carcinoma.

###### 

Multivariate analyses of prognostic factors in patients with thymic epithelial tumors.

  Parameter                           P-value   HR      95% CI
  ----------------------------------- --------- ------- ---------------
  FAK expression (low/high)           0.034     4.080   1.110--15.005
  Stage (I+II/III+IV)                 0.005     3.824   1.506--9.713
  Classification (A+AB+B1/B2+B3+TC)   0.110     2.548   0.808--8.032
  Tumor size (≤6/\>6 cm)              0.161     1.653   0.818--3.338

HR, hazard ratio; CI, confidence interval; FAK, focal adhesion kinase; TC, thymic carcinoma.
